비침습적 출생전 검사 시장 규모, 점유율, 동향 분석 리포트 : 임신 기간별, 임신 리스크별, 방법별, 기술별, 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Non Invasive Prenatal Testing Market Growth & Trends:

The global non invasive prenatal testing market size is expected to reach USD 8.16 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 10.06% from 2024 to 2030. Increasing incidence of chromosomal abnormalities is expected to accelerate market growth. Of all the countries, there is a substantial opportunity in China for non invasive prenatal screening, with nearly 14.65 million annual births and increasing number of high-risk pregnancies.

In addition, India has a heavy burden of genetic diseases. Various studies suggested that chromosomal abnormalities are found with a frequency of 1 in 166 newborns in the country, while trisomy 21 (Down syndrome) has a high incidence rate of 1 in 800 births, resulting in the birth of 32,000 newborns with Down syndrome every year. Families can benefit from accurate and early screening using NIPT to know about their baby's genetic issue. Thus, this high incidence rate is anticipated to boost the demand for prenatal tests.

With lockdowns due to COVID-19, NIPT gained attention because it delivers high accuracy screening with minimum risk of infection compared to invasive procedures like chorionic villus sampling and amniocentesis, both of which may necessitate hospitalization and put patients and medical professionals at risk of contracting COVID-19 infection. Moreover, there was increased demand for prescription of NIPTs; however, it was limited to a smaller number of eligible people due to the lack of infrastructure and adoption of telemedicine facilities in most countries.

The reimbursement scenario pertaining to non invasive prenatal testing is highly variable. However, the support from the government and favorable insurance policies boost market growth. For instance, in the Netherlands, prenatal testing expenses are fully reimbursed in the second trimester, leading to increased adoption of these tests. Increase in government initiatives to encourage the bio- and pharmaceutical industry in emerging economies such as India and China is anticipated to boost the demand for noninvasive prenatal testing solutions and services.

Key players in the market are focusing on new product development to strengthen their product portfolios and offer innovative products to customers. In March 2020, Agilent Technologies launched three new microarrays to support prenatal and postnatal research by cytogenetic laboratories. The probes on the cyto microarrays offer high-resolution detection of copy number variation and copy-neutral loss of heterozygosity related to neuropsychiatric disorders, developmental delay, intellectual disability, and congenital anomalies in constitutional DNA samples.

Non Invasive Prenatal Testing Market Report Highlights:

• By gestation period, 13-24 weeks dominated the market in 2023 owing to the maximum number of non-invasive prenatal procedures carried out in the second trimester of the pregnancy
• The low-risk pregnancy risk segment is expected to witness significant growth over the forecast period. Support from the government such as budget assignment for average-risk pregnancies contributed to the segment growth
• Based on product, the cell-free DNA in maternal plasma tests segment accounted for the largest revenue share in 2023. Cell-free DNA is increasingly being utilized in predicting the risk of genetic disorders in prenatal care via various genetic analyses
• Asia Pacific is expected to exhibit the highest CAGR over the forecast period. Rising maternal age and improving healthcare infrastructure are likely to strengthen the market growth
• North America dominated the market in 2023 due to high R&D investments, the presence of advanced healthcare facilities, and the development of whole genome sequencing

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation
  • 1.1.1. Market Definitions
• 1.2. Objectives
  • 1.2.1. Objective - 1
  • 1.2.2. Objective - 2
  • 1.2.3. Objective - 3
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. Gvr's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. List of Primary Sources

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers
  • 3.4.1. Increasing average maternal age and rising incidence of chromosomal syndromes
  • 3.4.2. High demand for early and noninvasive fetal testing procedure
  • 3.4.3. Improvements in the reimbursement scenario
  • 3.4.4. Rising collaborations and licensing agreements
• 3.5. Market Restraint Analysis
  • 3.5.1. Ethical concerns with respect to reproductive genetics
• 3.6. Business Environment Analysis
  • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
  • 3.6.2. Porter's Five Forces Analysis
  • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Gestation Period Business Analysis

• 4.1. Non-Invasive Prenatal Testing Market: Gestation Period Movement Analysis
• 4.2. 0-12 Weeks
  • 4.2.1. 0-12 Weeks Non-Invasive Prenatal Testing Market, 2018 - 2030 (USD Million)
• 4.3. 13-24 Weeks
  • 4.3.1. 13-24 Weeks Non-Invasive Prenatal Testing Market, 2018 - 2030 (USD Million)
• 4.4. 25-36 Weeks
  • 4.4.1. 25-36 Weeks Non-Invasive Prenatal Testing Market, 2018 - 2030 (USD Million)

Chapter 5. Pregnancy Risk Business Analysis

• 5.1. Non-Invasive Prenatal Testing Market: Pregnancy Risk Movement Analysis
• 5.2. High & Average Risk
  • 5.2.1. High & Average Risk Non-Invasive Prenatal Testing Market, 2018 - 2030 (USD Million)
• 5.3. Low Risk
  • 5.3.1. Low Risk Non-Invasive Prenatal Testing Market, 2018 - 2030 (USD Million)

Chapter 6. Method Risk Business Analysis

• 6.1. Non-Invasive Prenatal Testing Market: Method Movement Analysis
• 6.2. Ultrasound Detection
  • 6.2.1. Ultrasound Detection Non-Invasive Prenatal Testing Market, 2018 - 2030 (USD Million)
• 6.3. Biochemical Screening Tests
  • 6.3.1. Biochemical Screening Tests Non-Invasive Prenatal Testing Market, 2018 - 2030 (USD Million)
• 6.4. Cell-free DNA in Maternal Plasma Tests
  • 6.4.1. Cell-free DNA in Maternal Plasma Tests Non-Invasive Prenatal Testing Market, 2018 - 2030 (USD Million)

Chapter 7. Technology Risk Business Analysis

• 7.1. Non-Invasive Prenatal Testing Market: Technology Movement Analysis
• 7.2. NGS
  • 7.2.1. NGS Non-Invasive Prenatal Testing Market, 2018 - 2030 (USD Million)
• 7.3. Array Technology
  • 7.3.1. Array Technology Non-Invasive Prenatal Testing Market, 2018 - 2030 (USD Million)
• 7.4. PCR
  • 7.4.1. PCR Non-Invasive Prenatal Testing Market, 2018 - 2030 (USD Million)
• 7.5. Others
  • 7.5.1. Others Non-Invasive Prenatal Testing Market, 2018 - 2030 (USD Million)

Chapter 8. Product Risk Business Analysis

• 8.1. Non-Invasive Prenatal Testing Market: Product Movement Analysis
• 8.2. Consumables & Reagents
  • 8.2.1. Consumables & Reagents Non-Invasive Prenatal Testing Market, 2018 - 2030 (USD Million)
• 8.3. Instruments
  • 8.3.1. Instruments Non-Invasive Prenatal Testing Market, 2018 - 2030 (USD Million)

Chapter 9. Application Risk Business Analysis

• 9.1. Non-Invasive Prenatal Testing Market: Application Movement Analysis
• 9.2. TRISOMY
  • 9.2.1. TRISOMY Non-Invasive Prenatal Testing Market, 2018 - 2030 (USD Million)
• 9.3. Microdeletion Syndrome
  • 9.3.1. Microdeletion Syndrome Non-Invasive Prenatal Testing Market, 2018 - 2030 (USD Million)
• 9.4. Others
  • 9.4.1. Others Non-Invasive Prenatal Testing Market, 2018 - 2030 (USD Million)

Chapter 10. End-use Business Analysis

• 10.1. Non-Invasive Prenatal Testing Market: End-Use Movement Analysis
• 10.2. Hospitals & Clinics
  • 10.2.1. Hospitals & Clinics Market, 2018 - 2030 (USD Million)
• 10.3. Diagnostics Laboratories
  • 10.3.1. Diagnostics Laboratories Companies Market, 2018 - 2030 (USD Million)
• 10.4. Academic and Research Institutes
  • 10.4.1. Academic and Research Institutes Market, 2018 - 2030 (USD Million)

Chapter 11. Regional Business Analysis

• 11.1. Non-Invasive Prenatal Testing Market Share By Region, 2023 & 2030
• 11.2. North America
  • 11.2.1. North America Non-Invasive Prenatal Testing market, 2018 - 2030 (USD Million)
  • 11.2.2. U.S.
    • 11.2.2.1. Key Country Dynamics
    • 11.2.2.2. Target Disease Prevalence
    • 11.2.2.3. Competitive Scenario
    • 11.2.2.4. Regulatory Framework
    • 11.2.2.5. Reimbursement Scenario
    • 11.2.2.6. U.S. Non-Invasive Prenatal Testing market, 2018 - 2030 (USD Million)
  • 11.2.3. Canada
    • 11.2.3.1. Key Country Dynamics
    • 11.2.3.2. Target Disease Prevalence
    • 11.2.3.3. Competitive Scenario
    • 11.2.3.4. Regulatory Framework
    • 11.2.3.5. Reimbursement Scenario
    • 11.2.3.6. Canada Non-Invasive Prenatal Testing market, 2018 - 2030 (USD Million)
• 11.3. Europe
  • 11.3.1. Europe Non-Invasive Prenatal Testing market, 2018 - 2030 (USD Million)
  • 11.3.2. Germany
    • 11.3.2.1. Key Country Dynamics
    • 11.3.2.2. Target Disease Prevalence
    • 11.3.2.3. Competitive Scenario
    • 11.3.2.4. Regulatory Framework
    • 11.3.2.5. Reimbursement Scenario
    • 11.3.2.6. Germany Non-Invasive Prenatal Testing market, 2018 - 2030 (USD Million)
  • 11.3.3. UK
    • 11.3.3.1. Key Country Dynamics
    • 11.3.3.2. Target Disease Prevalence
    • 11.3.3.3. Competitive Scenario
    • 11.3.3.4. Regulatory Framework
    • 11.3.3.5. Reimbursement Scenario
    • 11.3.3.6. UK Non-Invasive Prenatal Testing market, 2018 - 2030 (USD Million)
  • 11.3.4. France
    • 11.3.4.1. Key Country Dynamics
    • 11.3.4.2. Target Disease Prevalence
    • 11.3.4.3. Competitive Scenario
    • 11.3.4.4. Regulatory Framework
    • 11.3.4.5. Reimbursement Scenario
    • 11.3.4.6. France Non-Invasive Prenatal Testing market, 2018 - 2030 (USD Million)
  • 11.3.5. Italy
    • 11.3.5.1. Key Country Dynamics
    • 11.3.5.2. Target Disease Prevalence
    • 11.3.5.3. Competitive Scenario
    • 11.3.5.4. Regulatory Framework
    • 11.3.5.5. Reimbursement Scenario
    • 11.3.5.6. Italy Non-Invasive Prenatal Testing market, 2018 - 2030 (USD Million)
  • 11.3.6. Spain
    • 11.3.6.1. Key Country Dynamics
    • 11.3.6.2. Target Disease Prevalence
    • 11.3.6.3. Competitive Scenario
    • 11.3.6.4. Regulatory Framework
    • 11.3.6.5. Reimbursement Scenario
    • 11.3.6.6. Spain Non-Invasive Prenatal Testing market, 2018 - 2030 (USD Million)
  • 11.3.7. Denmark
    • 11.3.7.1. Key Country Dynamics
    • 11.3.7.2. Target Disease Prevalence
    • 11.3.7.3. Competitive Scenario
    • 11.3.7.4. Regulatory Framework
    • 11.3.7.5. Reimbursement Scenario
    • 11.3.7.6. Denmark Non-Invasive Prenatal Testing market, 2018 - 2030 (USD Million)
  • 11.3.8. Sweden
    • 11.3.8.1. Key Country Dynamics
    • 11.3.8.2. Target Disease Prevalence
    • 11.3.8.3. Competitive Scenario
    • 11.3.8.4. Regulatory Framework
    • 11.3.8.5. Reimbursement Scenario
    • 11.3.8.6. Sweden Non-Invasive Prenatal Testing market, 2018 - 2030 (USD Million)
  • 11.3.9. Norway
    • 11.3.9.1. Key Country Dynamics
    • 11.3.9.2. Target Disease Prevalence
    • 11.3.9.3. Competitive Scenario
    • 11.3.9.4. Regulatory Framework
    • 11.3.9.5. Reimbursement Scenario
    • 11.3.9.6. Norway Non-Invasive Prenatal Testing market, 2018 - 2030 (USD Million)
• 11.4. Asia Pacific
  • 11.4.1. Asia Pacific Non-Invasive Prenatal Testing market, 2018 - 2030 (USD Million)
  • 11.4.2. Japan
    • 11.4.2.1. Key Country Dynamics
    • 11.4.2.2. Target Disease Prevalence
    • 11.4.2.3. Competitive Scenario
    • 11.4.2.4. Regulatory Framework
    • 11.4.2.5. Reimbursement Scenario
    • 11.4.2.6. Japan Non-Invasive Prenatal Testing market, 2018 - 2030 (USD Million)
  • 11.4.3. China
    • 11.4.3.1. Key Country Dynamics
    • 11.4.3.2. Target Disease Prevalence
    • 11.4.3.3. Competitive Scenario
    • 11.4.3.4. Regulatory Framework
    • 11.4.3.5. Reimbursement Scenario
    • 11.4.3.6. China Non-Invasive Prenatal Testing market, 2018 - 2030 (USD Million)
  • 11.4.4. India
    • 11.4.4.1. Key Country Dynamics
    • 11.4.4.2. Target Disease Prevalence
    • 11.4.4.3. Competitive Scenario
    • 11.4.4.4. Regulatory Framework
    • 11.4.4.5. Reimbursement Scenario
    • 11.4.4.6. India Non-Invasive Prenatal Testing market, 2018 - 2030 (USD Million)
  • 11.4.5. South Korea
    • 11.4.5.1. Key Country Dynamics
    • 11.4.5.2. Target Disease Prevalence
    • 11.4.5.3. Competitive Scenario
    • 11.4.5.4. Regulatory Framework
    • 11.4.5.5. Reimbursement Scenario
    • 11.4.5.6. South Korea Non-Invasive Prenatal Testing market, 2018 - 2030 (USD Million)
  • 11.4.6. Australia
    • 11.4.6.1. Key Country Dynamics
    • 11.4.6.2. Target Disease Prevalence
    • 11.4.6.3. Competitive Scenario
    • 11.4.6.4. Regulatory Framework
    • 11.4.6.5. Reimbursement Scenario
    • 11.4.6.6. Australia Non-Invasive Prenatal Testing market, 2018 - 2030 (USD Million)
  • 11.4.7. Thailand
    • 11.4.7.1. Key Country Dynamics
    • 11.4.7.2. Target Disease Prevalence
    • 11.4.7.3. Competitive Scenario
    • 11.4.7.4. Regulatory Framework
    • 11.4.7.5. Reimbursement Scenario
    • 11.4.7.6. Thailand Non-Invasive Prenatal Testing market, 2018 - 2030 (USD Million)
• 11.5. Latin America
  • 11.5.1. Latin America Non-Invasive Prenatal Testing market, 2018 - 2030 (USD Million)
  • 11.5.2. Brazil
    • 11.5.2.1. Key Country Dynamics
    • 11.5.2.2. Target Disease Prevalence
    • 11.5.2.3. Competitive Scenario
    • 11.5.2.4. Regulatory Framework
    • 11.5.2.5. Reimbursement Scenario
    • 11.5.2.6. Brazil Non-Invasive Prenatal Testing market, 2018 - 2030 (USD Million)
  • 11.5.3. Mexico
    • 11.5.3.1. Key Country Dynamics
    • 11.5.3.2. Target Disease Prevalence
    • 11.5.3.3. Competitive Scenario
    • 11.5.3.4. Regulatory Framework
    • 11.5.3.5. Reimbursement Scenario
    • 11.5.3.6. Mexico Non-Invasive Prenatal Testing market, 2018 - 2030 (USD Million)
  • 11.5.4. Argentina
    • 11.5.4.1. Key Country Dynamics
    • 11.5.4.2. Target Disease Prevalence
    • 11.5.4.3. Competitive Scenario
    • 11.5.4.4. Regulatory Framework
    • 11.5.4.5. Reimbursement Scenario
    • 11.5.4.6. Argentina Non-Invasive Prenatal Testing market, 2018 - 2030 (USD Million)
• 11.6. MEA
  • 11.6.1. MEA Non-Invasive Prenatal Testing market, 2018 - 2030 (USD Million)
  • 11.6.2. South Africa
    • 11.6.2.1. Key Country Dynamics
    • 11.6.2.2. Target Disease Prevalence
    • 11.6.2.3. Competitive Scenario
    • 11.6.2.4. Regulatory Framework
    • 11.6.2.5. Reimbursement Scenario
    • 11.6.2.6. South Africa Non-Invasive Prenatal Testing market, 2018 - 2030 (USD Million)
  • 11.6.3. Saudi Arabia
    • 11.6.3.1. Key Country Dynamics
    • 11.6.3.2. Target Disease Prevalence
    • 11.6.3.3. Competitive Scenario
    • 11.6.3.4. Regulatory Framework
    • 11.6.3.5. Reimbursement Scenario
    • 11.6.3.6. Saudi Arabia Non-Invasive Prenatal Testing market, 2018 - 2030 (USD Million)
  • 11.6.4. UAE
    • 11.6.4.1. Key Country Dynamics
    • 11.6.4.2. Target Disease Prevalence
    • 11.6.4.3. Competitive Scenario
    • 11.6.4.4. Regulatory Framework
    • 11.6.4.5. Reimbursement Scenario
    • 11.6.4.6. UAE Non-Invasive Prenatal Testing market, 2018 - 2030 (USD Million)
  • 11.6.5. Kuwait
    • 11.6.5.1. Key Country Dynamics
    • 11.6.5.2. Target Disease Prevalence
    • 11.6.5.3. Competitive Scenario
    • 11.6.5.4. Regulatory Framework
    • 11.6.5.5. Reimbursement Scenario
    • 11.6.5.6. Kuwait Non-Invasive Prenatal Testing market, 2018 - 2030 (USD Million)

Chapter 12. Competitive Landscape

• 12.1. Participant's overview
• 12.2. Financial performance
• 12.3. Participant categorization
  • 12.3.1. Market Leaders
  • 12.3.2. Non-Invasive Prenatal Testing market Share Analysis, 2023
  • 12.3.3. Company Profiles
    • 12.3.3.1. Genesis Genetics (CooperSurgical, Inc.)
    • 12.3.3.1.1. Company Overview
    • 12.3.3.1.2. Financial Performance
    • 12.3.3.1.3. Product Benchmarking
    • 12.3.3.1.4. Strategic Initiatives
    • 12.3.3.2. Natera, Inc.
    • 12.3.3.2.1. Company Overview
    • 12.3.3.2.2. Financial Performance
    • 12.3.3.2.3. Product Benchmarking
    • 12.3.3.2.4. Strategic Initiatives
    • 12.3.3.3. Centogene N.V.
    • 12.3.3.3.1. Company Overview
    • 12.3.3.3.2. Financial Performance
    • 12.3.3.3.3. Product Benchmarking
    • 12.3.3.3.4. Strategic Initiatives
    • 12.3.3.4. Eurofins Scientific
    • 12.3.3.4.1. Company Overview
    • 12.3.3.4.2. Financial Performance
    • 12.3.3.4.3. Product Benchmarking
    • 12.3.3.4.4. Strategic Initiatives
    • 12.3.3.5. MedGenome Labs Ltd.
    • 12.3.3.5.1. Company Overview
    • 12.3.3.5.2. Financial Performance
    • 12.3.3.5.3. Product Benchmarking
    • 12.3.3.5.4. Strategic Initiatives
    • 12.3.3.6. F. Hoffmann-La Roche Ltd. (Ariosa Diagnostics)
    • 12.3.3.6.1. Company Overview
    • 12.3.3.6.2. Financial Performance
    • 12.3.3.6.3. Product Benchmarking
    • 12.3.3.6.4. Strategic Initiatives
    • 12.3.3.7. Myriad Women's Health, Inc. (Counsyl, Inc.)
    • 12.3.3.7.1. Company Overview
    • 12.3.3.7.2. Financial Performance
    • 12.3.3.7.3. Product Benchmarking
    • 12.3.3.7.4. Strategic Initiatives
    • 12.3.3.8. Progenity, Inc.
    • 12.3.3.8.1. Company Overview
    • 12.3.3.8.2. Financial Performance
    • 12.3.3.8.3. Product Benchmarking
    • 12.3.3.8.4. Strategic Initiatives
    • 12.3.3.9. Qiagen
    • 12.3.3.9.1. Company Overview
    • 12.3.3.9.2. Financial Performance
    • 12.3.3.9.3. Product Benchmarking
    • 12.3.3.9.4. Strategic Initiatives
    • 12.3.3.10. Laboratory Corp. of America Holdings
    • 12.3.3.10.1. Company Overview
    • 12.3.3.10.2. Financial Performance
    • 12.3.3.10.3. Product Benchmarking
    • 12.3.3.10.4. Strategic Initiatives
    • 12.3.3.11. Illumina, Inc. (Verinata Health, Inc.)
    • 12.3.3.11.1. Company Overview
    • 12.3.3.11.2. Financial Performance
    • 12.3.3.11.3. Product Benchmarking
    • 12.3.3.11.4. Strategic Initiatives
    • 12.3.3.12. Quest Diagnostics, Inc.
    • 12.3.3.12.1. Company Overview
    • 12.3.3.12.2. Financial Performance
    • 12.3.3.12.3. Product Benchmarking
    • 12.3.3.12.4. Strategic Initiatives
  • 12.3.4. Strategy Mapping
    • 12.3.4.1. Expansion
    • 12.3.4.2. Acquisition
    • 12.3.4.3. Collaborations
    • 12.3.4.4. Product Type/Product Launch
    • 12.3.4.5. Partnerships
    • 12.3.4.6. Others